• We are available for your help 24/7
  • Email: info@isindexing.com, submission@isindexing.com


Paper Details

DPP 4 INHIBITORS: A NEW ERA OF TREATING TYPE 2 DIABETES MELLITUS

Jadav H*, Lad K, Jadav P

Journal Title:World Journal of Pharmaceutical Research
Abstract


Type 2 diabetes is a complex metabolic disorder, comprising altered insulin sensitivity and impaired insulin secretion. Now-a-days various treatments are available for the treatment of type 2 diabetes mellitus. Inhibition of dipeptidyl peptidase 4 (DPP-4) is a novel treatment for type-2 diabetes. In recent years, various DPP-4 inhibitors have been released as therapeutic drugs for type 2 diabetes. These agents inhibit thedegradation of the incretins glucagon -like peptide-1 (GLP-1) and glucose-dependent insulinotropicpolypeptide (GIP) and hence potentiate glucose-dependent insulin secretion.They are well-tolerated with no weight gain and few adverse effects, and, of particular interest, no increase in hypoglycemic episodes.DPP-4 inhibition is suggested to be a first-line treatment of type-2 diabetes, particularly in its early stages in combination with metformin. Several DPP-4 inhibitors are in clinical development, and many are already available in the market like sitagliptin, vildagliptinetc. some of them have patents for chemical entities for inhibiting DPP 4 enzyme in vitro and in vivo. However, further studies are needed to validate both longtermb-cell preservation and the role of these agents in the management of diabetes.The present review gives an inside out of the DPP IV inhibitors, novel drugs in clinical trials, patents and combination therapy with other anti diabetic drugs.

Download